A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake

Yujian Zhang, Johanna K. Hansen, Laiman Xiang, Seiji Kawa, Masanori Onda, Mitchell Ho, Raffit Hassan, and Ira Pastan

Abstract

Tumor microenvironments present significant barriers to penetration by antibodies, immunoconjugates, and other immunotoxins. In this report, we illustrate a novel strategy to increase tumor cell uptake of immunotoxin by combination with Taxol. SS1P is an immunotoxin composed of the Fv portion of a mesothelin-specific antibody fused to a bacterial toxin that is presently undergoing phase II testing in mesothelioma. Using novel flow cytometry and gel filtration methods, we quantified SS1P uptake in individual tumor cells along with levels of shed mesothelin (sMSLN), a barrier of SS1P therapy. The validity of our flow cytometric method was confirmed by the ability to similarly quantitate tumor cell uptake of Herceptin and an immunotoxin targeting HER2/neu. SS1P uptake peaked several hours after SS1P was cleared from the blood, reflecting an intratumor distribution process of SS1P that is independent of blood supply. Using the methods developed, we demonstrated that Taxol could improve SS1P penetration into tumors in parallel with an associated reduction of sMSLN in tumor extracellular fluid. Our findings offer a mechanistic rationale to combine SS1P with Taxol or another cytotoxic drug as a strategy to increase immunotoxin uptake by tumor cells. Further, we suggest one basis to understand why chemotherapy and antibody-based therapies cooperate when combined in cancer treatment. Cancer Res; 70(3); 1082–9. ©2010 AACR.

Introduction

Solid tumors remain a major therapeutic problem despite the large number of treatments available. Antibody-based therapies have shown great promise, but a major challenge is delivering sufficient amounts of antibody, immunoconjugate, or immunotoxin to all malignant cells within large tumor masses. To kill cells, these agents must be distributed to the tumor by blood vessels, escape from capillaries, and diffuse through the interstitial space to reach cells in the interior of the tumor. Several barriers to antibody penetration have been identified, including defective vasculature (1), a binding site barrier (2), high interstitial fluid pressure (3), high collagen composition (4), and the presence of high levels of shed antigen in the tumor (5).

Recombinant immunotoxins are genetically engineered proteins composed of the Fv portion of an antibody fused to a toxic protein designed to kill cancer cells (6). Two of these, Ontak (7) and BL22 (8), are very active in hematologic malignancies; however, immunotoxins are less active against solid tumors (9, 10).

Immunotoxin SS1P, currently in a phase II clinical trial, targets solid tumors with mesothelin expression. It is a 63,000 daltons protein with a half-life of 20 minutes in mice. The large molecular size, short half-life, and systemic toxicity limit its entry to tumor tissue. In addition, mesothelin is actively shed by tumors. Shed mesothelin (sMSLN) is present in tumor extracellular fluid (ECF) at a very high concentration and acts as a decoy receptor to prevent SS1P from targeting tumor cells (5). These factors make enhancing drug delivery into tumors critical to improve the therapeutic effect of SS1P.

In this study, we describe a new approach to study the targeting process of SS1P in tumors. Because only internalized SS1P can kill cancer cells, we developed a flow cytometry–based method (FC method) to measure both the percentage of cells in a tumor that accumulates SS1P and the average amount of SS1P internalized by these cells. Gel filtration assay was also developed to study the formation of SS1P/mesothelin complexes in tumor ECF. This approach showed that Taxol treatment improved SS1P penetration into tumors and increased the fraction of tumor cells that accumulate SS1P. We conclude that this effect of Taxol contributes to the remarkable synergy obtained when the two agents are used together. We also showed this new method can be used to study the uptake of Herceptin and an immunotoxin targeting HER2/neu.

Materials and Methods

Reagents. Immunotoxins SS1P, SS1P(E553D), and Erh38 were prepared as previously described (11). SS1P(E553D) is
an ADP-ribosylating mutant of SS1P, in which glutamic acid 553 of *Pseudomonas* exotoxin A was substituted by aspartic acid. It is a nontoxic form of SS1P, retaining full binding capacity (12). The Alexa labeling was done with Alexa Fluor Protein Labeling Kit (Invitrogen). SS1P was biotinylated with Sulfo-NHS-Biotinylation (Pierce). Rat anti-mouse CD16/32 and phycoerythrin-conjugated mouse anti-human epidermal growth factor receptor (EGFR) are from BD.

**Cell culture.** A431/H9 is a human mesothelin transfected A431 cell line. There are 5 × 10⁶ mesothelin molecules for binding on the surface of each A431/H9 cell. NIH-3T3/HER-2 is a gift from Dr. Peter L. Choyke (NIH, Bethesda, MD; ref. 13). It is a human HER-2–transfected NIH-3T3 cell line, with high HER-2 expression on the cell surface. KB and A431/H9 cells are grown in DMEM with 10% fetal bovine serum (FBS). NIH-3T3/HER-2 is maintained in RPMI 1640 (10% FBS).

**Tumor dissociation and cell labeling analysis.** Alexa-labeled immunotoxin or antibody was given i.v. in 200 μL of 0.9% NaCl with 0.2 mg/mL bovine serum albumin. Xenografted A431/H9 tumors were removed and minced. Tumor dissociation was performed with 0.2 units/mL Liberase III (Roche) and 0.1 mg/mL DNase I in Hank’s buffered salt solution. The incubation was at 37°C for 30 min of constant mixing. The cell suspension was passed through a cell strainer (50 μm). A431/H9 cells were identified by staining with PE-labeled anti-human EGFR. Rat anti-mouse CD16/32 (10 μg/mL) was used to block nonspecific binding to Fc receptor. When antibody was injected, tumor perfusion was performed to remove circulating antibody in the blood before tumor was harvested (14).

**Figure 1.** In vivo tumor cell staining by SS1P-Alexa. A, cell composition of tumor cell suspension. Tumor cell suspension prepared by digestion was stained by anti-EGFR PE and anti-F4/80 APC to distinguish A431/H9 cells and mouse macrophages. B, the staining of A431/H9 tumors. Control mice received saline (a). Mice bearing A431/H9 tumors received SS1P-Alexa488 of different doses: 4 μg (b), 20 μg (c), and 100 μg (d). After 3 h, the staining of SS1P-Alexa on tumor cells (gated population in A) was analyzed. Numbers denote the percentage of SS1P-Alexa–positive tumor cells as total of tumor cells. C, summary of tumor staining by increased doses of SS1P-Alexa. Data from Ba, Bb, Bc, and Bd were plotted. D, the effect of tumor size on tumor cell staining. Mice bearing A431/H9 tumors of various sizes (70, 170, 400, and 650 mm³) received 20 μg of SS1P-Alexa. Tumor cell staining after 3 h was measured (n = 5).

**The number of incorporated SS1P molecules.** One A431/H9 cell has 5 × 10⁶ sites for SS1P-Alexa binding. A fluorescence intensity after saturation by SS1P-Alexa of culture cells was used as a standard. In tumor experiments, mice received an injection of SS1P-Alexa. The mean fluorescence intensity (MFI) was measured for EGFR-positive cell population in tumor cell suspension. The MFI was compared with that of mice that received only saline treatment. The average number of cell-associated SS1P-Alexa was then calculated. Because surface SS1P-Alexa was completely removed during tumor digestion, the number actually represented internalized SS1P-Alexa molecules by A431/H9 tumor cells.

**Tumor experiments.** Tumor experiments were done as previously described (11). NIH-3T3/HER-2 (2.0 × 10⁶ cells) were used for implantation. The animal protocol was approved by the National Cancer Institute Animal Care and Use Committee.

**Mesothelin preparation.** Mesothelin was expressed and purified as a rabbit Fc fusion protein with a His tag (15). The fusion protein has a thrombin cleavage site between the rabbit IgG and the extracellular domain of mesothelin. After purification of Fc-mesothelin over Protein A Sepharose (Amersham), Fc-mesothelin was dialyzed against immobilized affinity chromatography A buffer [50 mmol/L NaPO₄H₂, 10 mmol/L imidazole, 500 mmol/L NaCl (pH 7.5)] in the presence of thrombin (200 units; GE Healthcare) at room temperature overnight. The cleaved mesothelin product was then purified from the remaining Fc protein by immobilized affinity chromatography on Ni
Sepharose High Performance resin (GE Healthcare) in a 2 mL column.

**ELISA assay for SS1P-biotin.** The concentration of SS1P-biotin was measured by ELISA. Briefly, microtiter plates were coated with 4 μg/mL goat anti-mouse IgG. After blocking, mouse anti-PE monoclonal antibody IP57 (4 μg/mL) was added for incubation. After four washes, SS1P-biotin samples with proteinase inhibitor cocktail III (Calbiochem) was added and incubated overnight at 4°C, followed by 45-min incubation with streptavidin–horseradish peroxidase (100 ng/mL). The color was developed by tetramethylbenzidine substrate (Pierce). The assay can detect SS1P-biotin concentration as low as 0.1 ng/mL.

**The characterization of SS1P and mesothelin in tumor ECF.** Tumor ECF was obtained by nylon mesh basket method as previously described (16). To analyze the formation of SS1P/mesothelin complex in tumor ECF, gel filtration studies were performed with a TSK G2000sw column (30 cm × 7.8 mm; TOSOH). Briefly, 100 μL of isolated ECF (diluted 1:10 in PBS) was loaded onto column. PBS was applied to the column at the flow rate of 0.6 mL/min. Fractions of 0.2 mL were collected. SS1P and mesothelin concentrations in each fraction were measured by ELISA.

**Statistics.** All data are presented as mean ± SD. Statistical differences between groups were measured by Student’s t test with two-tailed distribution. A P value of less than 0.05 was considered significant.

**Results**

**FC method for in vivo mesothelin targeting.** To measure SS1P uptake by cells in a tumor, we developed the FC method, which we designed to measure the percentage of tumor cells that accumulate SS1P in vivo. SS1P was labeled by a small and stable fluorophore, Alexa488. The resulting conjugate, SS1P-Alexa488, has the same activity in cell killing assays and antitumor activity in mice as SS1P. It is also very stable after uptake by tumor cells with a half-life of 40 hours (data not shown).

SS1P-Alexa488 was given i.v. to mice bearing A431/H9 tumors (150 mm³). Tumors were removed 3 hours later, and a single-cell suspension was prepared as described in Materials and Methods. The fluorescent signal of SS1P-Alexa488 on these cells was measured by flow cytometry. A431/H9 cells express a high level of mesothelin and EGFR on their cell surface. EGFR is used to identify and gate tumor cells because of its resistance to enzymatic digestion (Fig. 1A). Several different types of cells within the tumor were identified, including tumor cells (50%), macrophages (30%), endothelial cells (2%), and others.

The EGFR-positive tumor cell population was gated for the analysis of SS1P staining. Because the digesting enzymes completely removed surface-bound SS1P, this method specifically measured internalized SS1P. When 4 μg of SS1P-Alexa488 was given, 9.4% of tumor cells became SS1P positive. When 20 and 100 μg were given, the positive tumor cells increased to 36% and 93%. There is only a 0.6% background in the assay (Fig. 1B). Thus, the fraction of positive tumor cells is positively correlated with the dose of SS1P-Alexa488 (Fig. 1C).

In addition, we injected 20 μg of Alexa488-labeled immunotoxin BL22 that binds to human CD22, which is not expressed on A431/H9 cells (17). We also injected SS1P-Alexa488 (20 μg) into mice bearing A431 tumors that do not express mesothelin. No Alexa-positive tumor cells were detected in these experiments (data not shown). These results show that SS1P-Alexa488 uptake by A431/H9 cells is specifically mediated by mesothelin binding.

Figure 2. In vivo tumor cell staining by anti–HER-2 antibody (Herceptin) and immunotoxin (Erb38). Mice with NIH-3T3/HER2 tumors (~200 mm³) received either Herceptin (30 μg; A) or Erb38 (B). Tumor cells were defined as the CD45−/CD31− population. The staining was measured 24 h after Herceptin administration and 3 h after Erb38.
The effect of tumor size on SS1P uptake was evaluated by injecting 20 μg of SS1P-Alexa into mice with different size tumors. Figure 1D shows that the percentage of cells labeled at 3 hours is inversely related to tumor size with the highest uptake (48%) for the smallest tumor (75 mm³). The values decreased to 31% for 170 mm³ tumors, to 22% for 400 mm³ tumors, and to 10% for 650 mm³. Tumor cell staining of SS1P-positive tumor cells. The number in the left above the middle line is the MFI of tumor cell population.

**FC method for in vivo HER-2 targeting.** We also applied the FC method to study the in vivo targeting process of Herceptin, a humanized antibody targeting HER2/neu-expressing tumors. We labeled it with Alexa647, which is structurally similar to Alexa488 but brighter. At a dose of 30 μg, 24% of NIH-3T3/HER2 tumor cells became positive for Herceptin. Rituxan-Alexa647 was used as a negative control, and only 0.6% positive tumor cells were observed (Fig. 2A). We also applied the FC method to the anti-HER2/neu immunotoxin Erb38 (18); 33% of tumor cells were labeled at 20 μg of Erb38-Alexa647 and 98% at 100 μg. Only 1.5% of cells were labeled with immunotoxin HA22 targeting CD22 (Fig. 2B). These studies show that the FC method can have a wide range of applications in the study of antibody-based therapies.

**The kinetics of cellular uptake of SS1P in tumor.** The tumor digestion step in this FC method completely removes surface-bound SS1P and measures only internalized SS1P. To examine the kinetics of cellular accumulation of SS1P in tumors independent of tumor cell killing, we used an inactive SS1P mutant SS1P(E553D)-Alexa. A 20 μg dose was given to mice with 150 mm³ tumors. Figure 3A shows that the percentage of SS1P-Alexa-positive increases with time, peaking at 60% between 6 and 9 hours. The percentage increased to 30% at 16 hours, which reflects a combination of degradation and dilution by cell division.

The FC method allows one to calculate the average amount of SS1P taken up per cell by using the MFI and converting it to the number of molecules per cell (see Materials and Methods). Figure 3B shows that at 1 hour, when 20% of cells contain SS1P, there are 37,000 SS1P molecules per cell, and this increases to 110,000 molecules per cell at 6 hours (P < 0.01), when 60% of cells contain SS1P. Between 6 and 9 hours, there is a further increase. Representative SS1P staining of tumor cells at each time point is shown in Fig. 3C. These studies show that the FC method has an advantage over other methods because it quantifies the amount of study drug targeting tumor cells on a cellular basis.

**Synergy of Taxol and immunotoxin SS1P on mesothelin-expressing tumors.** We previously showed that Taxol and SS1P synergize to cause the regression or eradication of mesothelin-expressing A431/K5 and KB tumors (11, 16). Taxol was shown to significantly decrease the sMSLN level in tumor ECF, which constitutes a barrier for SS1P therapy. Similar results were also identified with the tumor model used in the current study. When one dose of Taxol or three doses of SS1P alone delayed tumor growth for ~5 days, combination therapy caused dramatic regressions on tumor growth with a nadir on day 15 (Fig. 4A). Taxol treatment reduced the sMSLN levels in both tumor ECF and serum ~3-fold (Fig. 4Ba and b).

We investigated whether reducing the sMSLN barrier by Taxol was associated with an improvement of cellular uptake of SS1P in tumors with the FC method. Mice with tumors received SS1P-Alexa alone or SS1P-Alexa proceeded by Taxol (Fig. 4C). Without Taxol, 35% of the tumor cells are positive for SS1P at 3 hours. The percentage increased to 43% 3 days after one dose of 20 mg/kg Taxol (P < 0.05) and to 57% after 50 mg/kg Taxol (P < 0.01). Taxol did not increase the cell surface expression of mesothelin (data not shown). We conclude that the increased cellular uptake of SS1P after Taxol administration results from improved SS1P penetration in tumor.

**Formation of SS1P/mesothelin complexes in tumor extracellular space.** To provide direct evidence that sMSLN can act as a barrier in tumors, we developed a gel filtration method to determine if SS1P in tumors was free or bound to...
mesothelin. SS1P entering a tumor is expected to form a complex with sMSLN. Figure 5A shows that the TSK column can resolve mesothelin, SS1P, and the complex. As standards, SS1P alone, purified mesothelin alone, and preformed SS1P/mesothelin complexes were each run over the column. The SS1P peak emerged at 7.8 mL, corresponding to 61 kDa. Mesothelin eluted at 7.2 mL, corresponding to an apparent MW of 73 kDa. Although this is much larger than the expected MW of 42 kDa (19), analysis by dynamic light scattering shows that mesothelin is a monomer (data not shown) and behaves aberrantly on the column. The mesothelin-

SS1P complex was prepared by mixing in a 1:1 molar ratio. A major peak was detected at 6.76 mL.

Tumor ECF was collected at 3 hours after SS1P-biotin injection and analyzed on the TSK column. Two SS1P peaks, Pc and Pf, were identified (Fig. 5B), corresponding to the complex and free SS1P. Further analysis showed that SS1P in Pf is damaged and unable to bind to mesothelin (data not shown). Two sMSLN peaks were identified, a large peak of free mesothelin and a smaller peak in the position of the complex.
Figure 6. Formation of SS1P/mesothelin complex in tumor. A, injected SS1P (blue) is transported into the tumor tissue. It distributes between tumor cells and tumor extracellular space. Excess SS1P in tumor ECF penetrates to reach more tumor cells. At the same time, it forms a complex (green) with sMSLN (light brown) over that area. Tumor periphery has the highest SS1P concentration because of rich vasculature, and tumor center has the lowest SS1P concentration. B, when Taxol is given, sMSLN level in tumor ECF is lowered. More excess SS1P in ECF is available for penetration. A larger fraction of tumor cells are stained by SS1P.

(Fig. 5C). This is the expected result because the concentration of free mesothelin greatly exceeds that of SS1P in the tumor extracellular space. We showed that the complex peak is SS1P mediated by using HA22 as a negative control. ECF from HA22-biotin–treated tumors has only one peak at the position of free SS1P (Fig. 5D). This study provides direct evidence that sMSLN in tumor ECF binds mesothelin, which can serve as a barrier to SS1P therapy.

Discussion

We have developed a new flow cytometry–based approach to study the targeting process of immunotoxins and antibodies within solid tumors. In this approach, the immunotoxin or antibody labeled with a fluorescent dye is injected into mice bearing solid tumors. After various time periods, the tumor is removed, separated into single tumor cells, and their content of immunotoxin was analyzed by flow cytometry. We initially applied this method to study the uptake of the SS1P immunotoxin targeting mesothelin, but subsequently have shown that the method works for both the Herceptin antibody and an immunotoxin targeting Her2/neu.

We also studied the formation of SS1P/sMSLN complexes in the tumor ECF by gel filtration chromatography. We then used these methods to examine the mechanism of synergy observed when mesothelin-expressing tumors are treated with Taxol and SS1P. We showed that prior Taxol treatment increases the percentage of tumor cells that accumulate SS1P and propose that this effect accounts for the synergy observed when the agents are used together.

Because solid tumors have no lymphatics, there is a major defect in perfusion and drugs can only enter by diffusion, a much slower process. In addition, the high interstitial fluid pressure in tumors further impairs drug entry and this is especially important for antibody-based drugs, which diffuse slowly because of their large size (20). Drug is also consumed by binding to ligands along the path of entry. Because immunotoxins have a relatively short life in the circulation (20 minutes in mice and 2–8 hours in humans), and because they cannot be given at very high doses due to nonspecific side effects, the time that the tumor is exposed to high immunotoxin concentrations is relatively short. Hence, improving penetration should have an important impact on their therapeutic effect.

FC method for in vivo targeting. Previously, uptake of antibodies and immunotoxins by tumors has been investigated using radiolabeling or by immunohistochemistry—methods that are difficult to quantify at a cellular level. In this study, we used Alexa-labeled immunotoxin. The Alexa molecules used are small (less than 1 kDa), stable across a broad pH range, and emit a strong fluorescent signal upon excitation. These properties make these fluorochromes ideal for tumor staining studies and enabled us to measure both the percentage of cells in the tumor taking up the immunotoxin and the amount taken up by single cells.

One feature of the method is that an enzymatic digestion step is used to dissociate tumor cells. This treatment completely removes mesothelin and SS1P bound to it from the cell surface and allowed us to quantify the number of molecules internalized, which are critical for immunotoxin activity. Other methods measure both bound and internalized molecules as well as molecules trapped in the ECF or by other cell types. In addition, when multicolor staining is used, cell populations, other than tumor cells, can be simultaneously studied for their contributions to the drug distribution.

Gel filtration study. Mesothelin is actively shed from the cell surface so that sMSLN exists in tumor ECF at high concentrations (16), where it should be able to form complexes with SS1P, preventing it from binding to tumor cells or diffusing further into the tumor. In this study, we analyzed the nature of SS1P in the tumor ECF by size exclusion chromatography and showed that it was present in complexes with mesothelin. The complex is a result of SS1P distribution between cellular components of tumor and ECF. Several factors affect its formation in the tumor, including the level of SS1P in the tumor, the time and distance SS1P penetrates, and

www.aacrjournals.org
the sMSLN level in ECF. Thus, the level of complex is closely associated with the SS1P targeting process.

**SS1P redistribution in tumor.** In mice, the half-life of SS1P in the circulation is ∼20 minutes, so that after 2 hours the immunotoxin is essentially gone from the circulation and not available for tumor uptake. We were surprised to find that tumor cell labeling increased for up to 6 hours. There is a clear discrepancy between the kinetics of SS1P in blood and tumor cell uptake. This finding indicates that significant amounts of the immunotoxin are being redistributed within the tumor after blood levels have decreased to insignificant levels. Because the immunotoxin we measure is within the cell, some of the increase observed at 6 hours could have been due to SS1P on the cell surface, which is subsequently internalized. To investigate this, we measured the rate of internalization of surface-bound SS1P into A431/H9 cells in vitro and found that the internalization is complete within 1 hour (data not shown). We think it is unlikely that internalization is much slower in vivo. Our data suggest that there may be a reservoir of SS1P in the tumor that supplies SS1P to the tumor cells for several hours after SS1P in the blood has been cleared. This is in accord with the model of Jain and colleagues who predicted that under some circumstances a “drug reservoir” is present in the tumor that allows drug to spread within the tumor independent of blood supply (21).

**Contribution of attenuated sMSLN barrier to Taxol and SS1P synergy.** Based on the results from the FC method and gel filtration study, we show in Fig. 6 how reduction of the sMSLN level in ECF and reduction of the site density barrier after Taxol treatment contributes to the improved antitumor effect (Fig. 6). The injection of 20 μg of SS1P gives a blood level of ∼20 μg/mL. SS1P immediately enters the tumor because of the large concentration gradient. Entry continues for 1 to 2 hours until the blood concentration decreases to insignificant levels (0.5 μg/mL). During this period, SS1P molecules move out of the capillary and into the tumor compartment where they initially bind to tumor cells closest to blood vessels. As SS1P molecules penetrate further, they reach more tumor cells. Along the path, they bind to sMSLN in tumor ECF, forming complexes. Because of the very large amounts of sMSLN in the ECF, the distance SS1P can penetrate is limited. ECF complex formation is a function of sMSLN levels and penetration distance. After Taxol treatment, sMSLN is decreased, allowing SS1P to reach more tumor cells.

**Overcome barriers by Taxol.** Increasing the SS1P dose to 100 μg overcame the barriers to entry so that more than 90% of the cells were labeled by 3 hours. Unfortunately, due to nonspecific liver damage, the maximum single dose of SS1P that can be safely given to a mouse is ∼20 μg. One way to increase the number of cells that can be reached by SS1P is to pretreat animals with Taxol. Taxol has several useful effects. One is to lower sMSLN levels, removing the decoy barrier (16); a second is to disrupt the close packing of tumor cells, reducing the site barrier (2); and a third is to lower interstitial pressure, which allows for more rapid entry of macromolecules like SS1P (3, 22). One reason for the decrease in mesothelin levels is cessation of production due to tumor cell death. A second is more rapid transfer from the tumor into the blood due to disruption of the tumor. This is consistent with the suggestion that the void space produced by cancer cell death enhances the spreading of oncolytic herpes simplex virus (23). Thus, Taxol treatment could be creating an environment that facilitates the diffusion of sMSLN.

**Implications for human studies.** We conducted this study to determine how to increase immunotoxin activity in solid tumors in humans. Based on our preclinical studies demonstrating increased antitumor activity of immunotoxins when given with chemotherapy, a phase II trial of SS1P in patients with mesothelioma has opened. In this trial, patients with pleural mesothelioma are treated with chemotherapy (cisplatin and pemetrexed) followed by immunotoxin SS1P. We have measured mesothelin expression (24), the sensitivity of mesothelioma cells from patients to SS1P (25), and the soluble mesothelin levels in several human mesotheliomas1; all these values are similar to the values we found in KB cells or KB tumors. Because KB tumors are effectively treated with a combination of chemotherapy and SS1P, we believe that our combinational approach will be of value in some of these patients.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

We thank Drs. Xing Du and Francis Mussai for providing Alexa-labeled BL22 and HA22, Drs. Peter L. Choyke and Hisataka Kobayashi for NIH-3T3/HER-2 cells, and Dawn A. Walker for reading the manuscript.

**Grant Support**

Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 6/29/09; revised 11/24/09; accepted 11/25/09; published OnlineFirst 1/26/10.

---

1 Unpublished data.

**References**

A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake

Yujian Zhang, Johanna K. Hansen, Laiman Xiang, et al.

Cancer Res 2010;70:1082-1089. Published OnlineFirst January 26, 2010.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-09-2405

Cited articles  This article cites 25 articles, 18 of which you can access for free at: http://cancerres.aacrjournals.org/content/70/3/1082.full.html#ref-list-1

Citing articles  This article has been cited by 11 HighWire-hosted articles. Access the articles at: /content/70/3/1082.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.